Phacilitate Leaders World 

Improving Immuno-oncology Patient Response Rates

Improving Immuno-oncology Patient Response Rates

Discover the four cornerstones of improving patient response rates. Combination therapies, precision medicine, trial design and regulatory challenges

This e-book explores the importance and challenges of improving patient response. It also provides in-depth analysis, insight and knowledge from the industry, including:

  • Developments in combination therapies and the impact on patient response rates
  • The use of precision medicine in immuno-oncology
  • The impact of trial design on patient response rates and rational trial design vs. empirical science
  • Regulatory challenges of immuno-oncology combinations with advanced therapy medicinal products


The common denominator across all of these insights is one of collaboration and partnerships, whether it’s between academia, biotech and big pharma, a sponsor and a vendor or two individuals with a common goal. Without ‘combinations’ and collaborations, we cannot hope to significantly improve patient response rates and, ultimately, improve the lives of patients in need.

View the ebook

Improving Immuno-oncology Patient Response Rates

  • Real thinking forward combining experts in the field from manufacturing, regulatory and value vision” – “great network with strong experience and sharing risks & opportunities
    Anne-Virginie Eggimann
    bluebird bio
  • Great program, great people, great venue.
    Klaus Kühlcke
  • Dynamic, interesting and highly interactive event that promotes exchange and networking in highly specialized field of gene therapy.
    Nathalie Clement
    Powell Gene Therapy Center, University of Florida
  • Phacilitate provides a unique forum, bringing together research, process development, and commercial leaders on the cutting edge of cell, gene, and immunotherapy. A great conference for anyone wanting a comprehensive view of the field.
    Dr James Trager
  • It was all business. I’ve never been to an event where over 80% of the conversations I had were constructive to my business objectives.
    Kurt Gielen
    Chemelot Campus B.V.
  • Great way to expand network with global experts in cell and gene therapy who are facing similar challenges.
    Steven Goodman